Christopher A. Kroeger, Chief Executive Officer of MapLight Therapeutics, Inc. (NASDAQ:MPLT), disclosed through a recent SEC filing that he sold shares of the company’s common stock totaling approximately $3.21 million on May 18, 2026. The specific transactions involved the disposition of 118,235 shares of MapLight Therapeutics' voting common stock.
Details regarding these sales indicate that they were executed at various prices, ranging from a low of $26.565 to a high of $28.20 per share. These dispositions were not singular events; rather, the shares were sold across multiple transactions, resulting in weighted average prices calculated at $27.19 and $28.15 for different blocks of stock.
Crucially, these sales were conducted pursuant to a pre-established trading arrangement known as a Rule 10b5-1 plan. Mr. Kroeger had initially adopted this specific trading plan on December 29, 2025. Following the completion of these transactions, records show that Mr. Kroeger retained direct ownership of 1,394,094 shares of MapLight Therapeutics' voting common stock.
The timing of Mr. Kroeger’s sales is notable when viewed against recent market movements for MPLT. Data from InvestingPro indicates that the stock has experienced a decline of roughly 13% over the preceding week. However, the analysis also points to a more sustained performance trend, noting that the shares have risen approximately 82% over the last six months.
Despite the recent weekly dip, external analysis suggests that MPLT's stock may currently be undervalued. InvestingPro provides additional insights into this valuation assessment, including comprehensive Fair Value assessments and access to over eight additional ProTips for subscribers of the service.
In parallel with these insider transactions, MapLight Therapeutics has achieved several significant milestones related to its clinical development pipeline. The company recently announced the successful completion of enrollment in its Phase 2 ZEPHYR trial, which is investigating ML-007C-MA for the treatment of schizophrenia. Furthermore, the company confirmed the final patient visit for its Phase 2 IRIS trial, focusing on ML-004 for autism spectrum disorder.
The timeline for reporting topline results from both these major trials has been set for mid-August 2026. This clinical progress has drawn positive attention from financial analysts. Specifically, TD Cowen initiated coverage of MapLight Therapeutics with a 'buy' rating, placing emphasis on the company’s robust pipeline dedicated to central nervous system and neuropsychiatric conditions. The firm’s focus is particularly directed toward the lead asset, ML-007C-MA, anticipating Phase II data in the third quarter of the current year.
Adding to this positive analyst sentiment, Stifel reiterated its 'Buy' rating for MapLight Therapeutics and maintained a price target of $28.00, following the release of the company’s fourth-quarter update. Stifel’s analysis highlighted that the Phase 2 data for ML-007C-MA is on track to be read out in the third quarter of 2026. The firm's assessment suggests looking for confirmation of efficacy, along with potential differentiation in tolerability, safety profile, or through the implementation of once-daily dosing.
Risks
- <strong>Market Volatility and Recent Decline:</strong> The stock has declined approximately 13% in the past week, indicating short-term market sensitivity despite longer-term gains.
- <strong>Reliance on Future Data Readouts:</strong> The company's valuation is heavily predicated on receiving topline results from both Phase 2 trials (ZEPHYR and IRIS) by mid-August 2026. Failure to meet these timelines or achieving suboptimal data could impact confidence.
- <strong>Regulatory and Clinical Uncertainty:</strong> Although analysts are looking for differentiation in tolerability, safety, or dosing, the ultimate success of ML-007C-MA and other pipeline assets remains subject to clinical outcomes and regulatory approval processes.
More from Insider Trading
Risks
- <strong>Market Volatility and Recent Decline:</strong> The stock has declined approximately 13% in the past week, indicating short-term market sensitivity despite longer-term gains.
- <strong>Reliance on Future Data Readouts:</strong> The company's valuation is heavily predicated on receiving topline results from both Phase 2 trials (ZEPHYR and IRIS) by mid-August 2026. Failure to meet these timelines or achieving suboptimal data could impact confidence.
- <strong>Regulatory and Clinical Uncertainty:</strong> Although analysts are looking for differentiation in tolerability, safety, or dosing, the ultimate success of ML-007C-MA and other pipeline assets remains subject to clinical outcomes and regulatory approval processes.